Fresenius Medical Care Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Fresenius Medical Care kazanç ve gelirin sırasıyla yıllık 19.3% ve 3.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 18% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 7.7% olacağı tahmin edilmektedir.
Anahtar bilgiler
19.3%
Kazanç büyüme oranı
18.0%
EPS büyüme oranı
| Healthcare kazanç büyümesi | 27.7% |
| Gelir büyüme oranı | 3.8% |
| Gelecekteki özkaynak getirisi | 7.7% |
| Analist kapsamı | Good |
| Son güncelleme | 18 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
What Is Fresenius Medical Care AG's (ETR:FME) Share Price Doing?
Nov 21
Fresenius Medical Care AG (ETR:FME) Not Flying Under The Radar
Nov 01We Think Fresenius Medical Care (ETR:FME) Is Taking Some Risk With Its Debt
Sep 26These Return Metrics Don't Make Fresenius Medical Care (ETR:FME) Look Too Strong
Sep 08At €34.34, Is Fresenius Medical Care AG (ETR:FME) Worth Looking At Closely?
Aug 20Fresenius Medical Care AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 02These 4 Measures Indicate That Fresenius Medical Care (ETR:FME) Is Using Debt Extensively
Jun 17What You Can Learn From Fresenius Medical Care AG's (ETR:FME) P/E
May 30Some Shareholders May Object To A Pay Rise For Fresenius Medical Care AG's (ETR:FME) CEO This Year
May 10Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19
Apr 26Fresenius Medical Care's (ETR:FME) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 29Fresenius Medical Care (ETR:FME) Has Announced That It Will Be Increasing Its Dividend To €1.19
Mar 14Fresenius Medical Care's (ETR:FME) Dividend Will Be Increased To €1.19
Feb 23When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Feb 22Market Participants Recognise Fresenius Medical Care AG's (ETR:FME) Earnings
Feb 03Fresenius Medical Care (ETR:FME) Could Be Struggling To Allocate Capital
Jan 16Is Fresenius Medical Care (ETR:FME) Using Too Much Debt?
Dec 29Is There Now An Opportunity In Fresenius Medical Care AG & Co. KGaA (ETR:FME)?
Nov 21Capital Allocation Trends At Fresenius Medical Care KGaA (ETR:FME) Aren't Ideal
Oct 16Is Fresenius Medical Care KGaA (ETR:FME) A Risky Investment?
Sep 28Is Now The Time To Look At Buying Fresenius Medical Care AG & Co. KGaA (ETR:FME)?
Aug 21An Intrinsic Calculation For Fresenius Medical Care AG & Co. KGaA (ETR:FME) Suggests It's 34% Undervalued
Jul 23Returns On Capital At Fresenius Medical Care KGaA (ETR:FME) Paint A Concerning Picture
Jul 09These 4 Measures Indicate That Fresenius Medical Care KGaA (ETR:FME) Is Using Debt Extensively
Jun 25What Does Fresenius Medical Care AG & Co. KGaA's (ETR:FME) Share Price Indicate?
May 07Is There An Opportunity With Fresenius Medical Care AG & Co. KGaA's (ETR:FME) 49% Undervaluation?
Apr 23Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 20,632 | 1,103 | 1,878 | 2,713 | 16 |
| 12/31/2025 | 19,870 | 937 | 1,956 | 2,562 | 18 |
| 12/31/2024 | 19,257 | 678 | 1,783 | 2,572 | 18 |
| 9/30/2024 | 19,239 | 659 | 1,538 | 2,274 | N/A |
| 6/30/2024 | 19,415 | 530 | 1,342 | 2,049 | N/A |
| 3/31/2024 | 19,474 | 484 | 1,911 | 2,613 | N/A |
| 12/31/2023 | 19,454 | 499 | 1,918 | 2,629 | N/A |
| 9/30/2023 | 19,463 | 450 | 1,799 | 2,509 | N/A |
| 6/30/2023 | 19,622 | 596 | 1,674 | 2,407 | N/A |
| 3/31/2023 | 19,554 | 602 | 1,401 | 2,152 | N/A |
| 12/31/2022 | 19,398 | 673 | 1,397 | 2,167 | N/A |
| 9/30/2022 | 19,048 | 763 | 1,444 | 2,237 | N/A |
| 6/30/2022 | 18,393 | 806 | 1,444 | 2,271 | N/A |
| 3/31/2022 | 17,957 | 878 | 1,576 | 2,441 | N/A |
| 12/31/2021 | 17,619 | 969 | 1,603 | 2,489 | N/A |
| 9/30/2021 | 17,372 | 918 | 1,477 | 2,405 | N/A |
| 6/30/2021 | 17,344 | 998 | 1,480 | 2,459 | N/A |
| 3/31/2021 | 17,581 | 1,131 | 2,869 | 3,857 | N/A |
| 12/31/2020 | 17,859 | 1,164 | 3,148 | 4,233 | N/A |
| 9/30/2020 | 18,039 | 1,330 | 3,299 | 4,420 | N/A |
| 6/30/2020 | 18,044 | 1,309 | 3,377 | 4,542 | N/A |
| 3/31/2020 | 17,832 | 1,212 | 1,832 | 3,075 | N/A |
| 12/31/2019 | 17,477 | 1,200 | 1,404 | 2,567 | N/A |
| 9/30/2019 | 17,196 | 1,282 | 1,367 | 2,494 | N/A |
| 6/30/2019 | 16,835 | 1,234 | 1,246 | 2,379 | N/A |
| 3/31/2019 | 16,704 | 1,974 | 1,065 | 2,182 | N/A |
| 12/31/2018 | 16,547 | 1,982 | 920 | 2,062 | N/A |
| 9/30/2018 | 16,676 | 1,951 | 766 | 1,892 | N/A |
| 6/30/2018 | 16,954 | 1,975 | N/A | 1,750 | N/A |
| 3/31/2018 | 17,211 | 1,250 | N/A | 1,977 | N/A |
| 12/31/2017 | 17,784 | 1,280 | N/A | 2,192 | N/A |
| 9/30/2017 | 17,771 | 1,249 | N/A | 2,436 | N/A |
| 6/30/2017 | 17,647 | 1,244 | N/A | 2,217 | N/A |
| 3/31/2017 | 17,201 | 1,239 | N/A | 1,938 | N/A |
| 12/31/2016 | 16,570 | 1,144 | N/A | 1,932 | N/A |
| 9/30/2016 | 16,101 | 1,063 | N/A | 1,648 | N/A |
| 6/30/2016 | 15,841 | 998 | N/A | 1,782 | N/A |
| 3/31/2016 | 15,402 | 933 | N/A | 1,491 | N/A |
| 12/31/2015 | 15,455 | 955 | N/A | 1,767 | N/A |
| 9/30/2015 | 15,345 | 939 | N/A | 1,791 | N/A |
| 6/30/2015 | 15,246 | 948 | N/A | 1,914 | N/A |
| 3/31/2015 | 15,428 | 977 | N/A | 2,044 | N/A |
| 12/31/2014 | 13,329 | 864 | N/A | 1,538 | N/A |
| 9/30/2014 | 12,413 | 839 | N/A | 1,476 | N/A |
| 6/30/2014 | 11,112 | 775 | N/A | 1,283 | N/A |
| 3/31/2014 | 10,882 | 791 | N/A | 1,329 | N/A |
| 12/31/2013 | 10,816 | 806 | N/A | 1,478 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: FME 'nin tahmini kazanç büyümesi (yıllık 19.3% ) tasarruf oranının ( 1% ) üzerindedir.
Kazançlar ve Piyasa: FME şirketinin kazançlarının (yıllık 19.3% ) German pazarından (yıllık 21.1% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: FME şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: FME şirketinin gelirinin (yıllık 3.8% ) German pazarından (yıllık 5.7% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Geliri: FME şirketinin gelirinin (yıllık 3.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: FME 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 7.7 %).